nonsulfhydryl血管紧张素转换酶抑制剂卡托普利。

文章的细节

引用

复制到剪贴板

Vlasses PH值,拉里贾尼通用电气、RK康纳DP,弗格森

nonsulfhydryl血管紧张素转换酶抑制剂卡托普利。

中国制药。1985;1 - 2月4 (1):27-40。

PubMed ID

2982541 (在PubMed

]

文摘

化学、药理学、药物动力学、临床疗效、不良反应、马来酸和剂量卡托普利,nonsulfhydryl血管紧张素转换酶(ACE)抑制剂,进行了综述。卡托普利迅速转换通过酯水解依那普利,一个强有力的血管紧张素转化酶抑制剂;卡托普利本身只是一个软弱的ACE抑制剂。卡托普利降低外周血管阻力不会引起心率的增加。在充血性心力衰竭患者,卡托普利有益的血流动力学影响基于降低心脏前负荷和后负荷。大约60%的剂量卡托普利口服后吸收。依那普利主要是肾的排泄。依那普利积累发生在患者肌酐间隙小于30毫升/分钟。卡托普利10-40 mg每日口服的显示效果与卡托普利治疗患者温和,温和,和严重的高血压,高血压肾动脉狭窄所致,在充血性心力衰竭对洋地黄、利尿剂。当单独给予高血压、卡托普利的功效与噻嗪类利尿剂和β受体阻滞剂。 Side effects observed with enalapril have generally been minor. Captopril-associated side effects such as skin rash, loss of taste, and proteinuria have been observed in a small number of patients receiving enalapril to date; neutropenia less than 300/mm3 has been noted with captopril but not enalapril. The incidence of these side effects has been noted to be greatly decreased in patients on low doses of captopril. Enalapril appears to be similar in efficacy to captopril for treating hypertension and congestive heart failure. Whether enalapril is safer than low-dose captopril in patients at high risk for captopril-associated side effects will require further investigation.

DrugBank数据引用了这篇文章

药物

卡托普利